TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $41.00 at HC Wainwright

TG Therapeutics (NASDAQ:TGTX – Free Report) had its price objective lifted by HC Wainwright from $34.00 to $41.00 in a research report released on Tuesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for TG Therapeutics’ Q3 2023 earnings at ($0.19) EPS, Q4 2023 […]

Related Keywords

,Tg Therapeutics Company Profile ,Vanguard Group Inc ,Securities Exchange Commission ,Darwin Global Management Ltd ,Tg Therapeutics Inc ,Alkeon Capital Management ,Cantor Fitzgerald ,Blackrock Inc ,Goldman Sachs Group ,Free Report ,Stock Down ,Get Free Report ,Director Sagar Lonial ,Exchange Commission ,Street Corp ,Global Management ,Capital Management ,Tg Therapeutics ,Nasdaq Tgtx ,Tgtx ,Medical ,Boost Price Target ,Hc Wainwright ,